GSK's BLENREP Approved in China for Multiple Myeloma
Ticker: GSK · Form: 6-K · Filed: Apr 20, 2026 · CIK: 0001131399
Sentiment: bullish
Topics: regulatory-approval, china, oncology, drug-launch
TL;DR
GSK's BLENREP gets China nod for multiple myeloma, big win for oncology.
AI Summary
GSK plc announced on April 20, 2026, that its drug BLENREP has been approved in China for the treatment of relapsed or refractory multiple myeloma in adults who have received at least two prior therapies. This approval marks a significant step in expanding access to this treatment option for patients in China.
Why It Matters
The approval of BLENREP in China expands treatment options for multiple myeloma patients and represents a key market entry for GSK's oncology portfolio.
Risk Assessment
Risk Level: low — This filing is an announcement of regulatory approval, which is generally positive news with low inherent risk.
Key Players & Entities
- GSK plc (company) — Filer of the report and developer of BLENREP
- BLENREP (drug) — The drug that received approval
- China (country) — Location of the regulatory approval
- multiple myeloma (disease) — The condition BLENREP is approved to treat
FAQ
What is the specific indication for BLENREP's approval in China?
BLENREP is approved in China for the treatment of relapsed or refractory multiple myeloma in adults who have received at least two prior therapies.
What is the filing date of this report?
The filing date is April 20, 2026.
What is the accession number for this SEC filing?
The SEC accession number is 0001654954-26-003693.
What is GSK plc's mailing address?
GSK plc's mailing address is 79 NEW OXFORD STREET LONDON United Kingdom WC1A 1DG.
What type of form is this SEC filing?
This is a Form 6-K, Report of foreign issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 20, 2026 regarding GSK plc (GSK).